Get started
Author

Alberto Santagostino

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024 · Xavier Leleu, Cyrille Hulin, et al. · Nature Medicine · 134
PDF
Azacitidine for the treatment of patients with acute myeloid leukemia
2011 · Luca Maurillo, Adriano Venditti, et al. · Cancer · 129
An Italian national multicenter study for the definition of reference ranges for normal values of peripheral blood lymphocyte subsets in healthy adults.
1999 · A Santagostino, G Garbaccio, et al. · PubMed · 120
Prognostic impact ofDDX41germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
2022 · Nicolas Duployez, Laëtitia Largeaud, et al. · Blood · 95
PDF
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
2013 · Alessandra Larocca, Vittorio Montefusco, et al. · Blood · 85
PDF
The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia clinical results in 46 patients
1993 · Enrica Morra, Mario Lazzarino, et al. · Cancer · 57
PDF
Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study
2015 · Annalisa Arcari, Annalisa Chiappella, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 35
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
2022 · Pierre-Yves Dumas, Emmanuel Raffoux, et al. · Leukemia · 34
PDF
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
2021 · Francois Guilhot, Françoise Rigal-Huguet, et al. · Leukemia · 30
Atypical Takotsubo syndrome during anagrelide therapy
2009 · Riccardo Proietti, Andrea Rognoni, et al. · Journal of Cardiovascular Medicine · 26
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
2024 · Sylvain Garciaz, Pierre‐Yves Dumas, et al. · American Journal of Hematology · 25
PDF
Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study
2023 · Sylvain Garciaz, Sarah Bertoli, et al. · Blood · 14
A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide
2011 · Antonio Palumbo, Alessandra Larocca, et al. · Blood · 14
Staging of Primary Abdominal Lymphomas: Comparison of Whole-Body MRI with Diffusion-Weighted Imaging and18F-FDG-PET/CT
2015 · Alessandro Stecco, Francesco Buemi, et al. · Gastroenterology Research and Practice · 13
PDF
Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
2022 · Louise Laloi, Natacha Chaumard Billotey, et al. · Cancer Medicine · 11
PDF
Acute Kidney Injury Following High-Dose Methotrexate Administration in a Day Care Hospital
2019 · Srimanta Chandra Misra, Alberto Santagostino, et al. · Drug Safety - Case Reports · 6
PDF
Paroxysmal Nocturnal Hemoglobinuria with a Distinct Molecular Signature Diagnosed Ten Years after Allogenic Bone Marrow Transplantation for Acute Myeloid Leukemia
2019 · Alberto Santagostino, Laura Lombardi, et al. · Case Reports in Hematology · 6
PDF
Two Cases of Secondary Sotf Tissue Sarcomas after Radiotherapy and Radiochemotherapy
2004 · Chiara Saggia, Giorgio Forti, et al. · Tumori Journal · 6
Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study
2025 · Corentin Orvain, Suzanne Tavitian, et al. · HemaSphere · 5
PDF
5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients.
2008 · Luca Maurillo, Alessandra Spagnoli, et al. · Blood · 4
Pericardial Metastases in a Long-Surviving Patient with Sigmoid Carcinoma
2005 · Sara Lattuada, Chiara Saggia, et al. · Tumori Journal · 4
Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)
2025 · Anne Quinquenel, Stéphane Leprêtre, et al. · Annals of Hematology · 3
PDF
Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)
2022 · Sylvain Garciaz, Justine Decroocq, et al. · Blood · 3
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Results from ISASOCUT (IFM 2022–05)
2025 · Arthur Bobin, Anais Schavgoulidze, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study
2024 · Corentin Orvain, Suzanne Tavitian, et al. · Blood · 2
Works count: 45
Citation count: 872
H-index: 13
I10-index: 15
Year
Topic
Type